Abstract
That the pharmaceutical industry is undergoing a period of great transformation can be in little doubt, with so many industry reports highlighting the magnitude of the impact of the patent cliff on big pharma revenues and share prices.
…transformation is everybody’s job (Deming 2000 )
[Deming: Principles for Transformation]
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
(2001) Parliament E Article 111(6) of directive 2001/83/EC. (EC), E. C., Ed
(2013) EudraGMP, EudraGMDP _European medicines agency on-line database for MIA’s and GMP certs. EMA
Center EYGLS (2013) Closing the gap? Big pharma’s growth challenge and implications for deals. January
Deloitte (2013) Global life sciences outlook ‘optimism tempered by reality in a “new normal”’
Deming WE (2000) Out of the crisis. 1st MIT Press edn. MIT Press, Cambridge, p xiii, 507 p
EMA (2012a) Reflection paper on medicinal product supply shortages caused by manufacturing/good manufacturing practice compliance problems. Nov 2012
EMA (2012b) Guideline on process validation-draft. Agency, E. M., Ed. March 2012
FDA (2011a) A review of FDA’s approach to medical product shortages. October 2011.
FDA (2011b) Guidance for industry, process validation: general principles and practices. Current Good Manufacturing Practices (CGMP) revision 1 edn. FDA Ed. January 2011, p 19
FDA (2011c) Advancing regulatory science at FDA: a strategic plan; August 2011
FiercePharma (2013) Top 15 drug patent losses for 2013. http://www.fiercepharma.com/special-reports/top-15-patent-expirations-2013#ixzz2QFdMc824. Nov 2012
Friedli T (2012) Mastering plant complexity and the impact of operational excellence. In: global pharma manufacturing summit. New Jersey
Grady Denise PA, Tavernise Sabrina (2012) Scant oversight of drug maker in fatal meningitis outbreak. Wall Street J. 06 Oct 2012
ICH Q-IWG (2012) Introduction to ICH and the new quality paradigm. In: Robert JL (ed) Integrated training programme. ICH, Washington, DC
ICH (2008) ICH harmonised tripartite guideline: pharmaceutical quality system Q10. ICH, Ed. June 2008
ICH (2009a) ICH harmonised tripartite guideline: pharmaceutical development Q8(R2). ICH, Ed. Aug 2009
ICH (2009b) ICH harmonised tripartite guideline: quality risk management Q9. ICH, Ed. Nov 2009
ICH (2012) Development and manufacture of drug substances (chemical entities and biotechnological/biological entities) Q11. ICH. 1 May 2012
Margaret A, Hamburg MD (2013a) Weaving new threads in FDA’s global safety net. FDA. 22 Feb 2013
Margaret A, Hamburg MD (2013) Address to the annual meeting generic pharmaceutical manufacturers association on the prioritization of product quality. FDA. 22 Feb 2013
McLaughlin T (2012) New England compounding center, pharmacy linked to meningitis outbreak, files for bankruptcy. Huffington Post 21 Dec 2012
News C (2013) Lethal medicine linked to meningitis outbreak. 10 Mar 2013
Nonaka Ikujiro NT Knowledge emergence. Oxford University Press.
Nonaka I, Toyama R, Konno N (2000) SECI, Ba and leadership: a unified model of dynamic knowledge creation. Long Range Plann 33:5–34
O’Donnell K, Irish Medicines Board (IMB) (2012) Quality defect and product recall statistics, 2004–2011. IMB ‘Industry Open Day’ seminar 2012, 27 Sept 2012
ShaAvhrée Buckman-Garner M (2013) How FDA promotes partnerships to accelerate medical product development. FDA
Skibo AR (2013) Outsourcing & emerging markets v’s quality and drug availability. In: Creating, implementing and sustaining a culture of quality-putting the c into cGMP. ISPE, Baltimore
Transfer Center for Technology Management (2012) U. o. S. G. operational excellence in the pharmaceutical industry. http://www.opexbenchmarking.com. Accessed Dec 2012
Woodcock J (2012) Reliable drug quality: an unresolved problem. J Pharm Sci Technol 66(3):270–272
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Calnan, N. (2013). Leading the Advance in Regulatory Science. In: Friedli, T., Basu, P., Bellm, D., Werani, J. (eds) Leading Pharmaceutical Operational Excellence. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-35161-7_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-35161-7_5
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-35160-0
Online ISBN: 978-3-642-35161-7
eBook Packages: Business and EconomicsBusiness and Management (R0)